Regeneron announces data from Phase 1/2 LINKER-MM4 trial

Regeneron (REGN) Pharmaceuticals announced data from the Phase 1/2 LINKER-MM4 trial evaluating Lynozyfic in adults with newly diagnosed multiple myeloma who were transplant eligible or ineligible were shared in an oral presentation at the American Society of Hematology Annual Meeting. These data build on results from a broad clinical development program evaluating Lynozyfic in early lines of treatment, including precursor conditions, as monotherapy and in combination with standard-of-care or novel agents. Key points: All three dose groups showed impressive monotherapy efficacy, with VGPR+ of greater than or equal to70% despite limited follow-up; evidence shows that these responses are expected to deepen over time; Across all dose groups, 95% of all evaluable VGPR+ patients achieved minimal residual disease negative status; Data featured in an ASH oral presentation; LINKER-MM4 is the first clinical trial to evaluate a BCMAxCD3 bispecific monotherapy in NDMM and is part of a broad clinical development program evaluating Lynozyfic-based regimens in earlier lines of treatment